Wuhan YZY Biopharma Co., Ltd. (SEHK: 2496)
Health Care · Biotechnology · CN
HK$3.50
+40.00% today · -48.5% 1Y
Wuhan YZY Biopharma Co., Ltd. (SEHK: 2496) operates in the Biotechnology industry within the Health Care sector. The company is valued at $86.45M and employs 106 people.
Over the last twelve months the share price has lost 48.5%, trading between 2.20 and 8.40.
Tweenvest scores Wuhan YZY Biopharma Co., Ltd. across four factors: quality 19/100, value 72/100. Its strongest factor is value.
2496 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $86.45M
- Revenue (TTM)
- $8.58M
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 0.48
- 52-week high
- HK$8.40
- 52-week low
- HK$2.20
- Avg volume (3M)
- —
- Shares outstanding
- 193.85M
- Employees
- 106
- Next earnings
- —
About Wuhan YZY Biopharma Co., Ltd.
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
- ISIN
- CNE1000063C4
- Founded
- 2010
- Listed since
- Sep 26, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.NasdaqCM: CRBP | $87.42M | $4.52 | -15.99% |
| Inovio Pharmaceuticals, Inc.NasdaqCM: INO | $87.20M | $0.84 | +6.04% |
| Revium Rx.OTCPK: RVRC | $86.84M | $— | — |
| Rallybio CorporationNasdaqCM: RLYB | $86.45M | $16.28 | -4.35% |
| Bonraybio Co., Ltd.TWSE: 6955 | $86.43M | NT$92.30 | -0.75% |
| Conexeu Sciences Inc.NasdaqCM: CNXU | $86.31M | $3.06 | -21.34% |
| Quantum Cyber N.V.NasdaqCM: QUCY | $85.75M | $1.02 | -4.67% |
| Tenaya Therapeutics, Inc.NasdaqCM: TNYA | $85.36M | $0.38 | -34.40% |
Figures last refreshed Oct 18, 2026.